Teva Pharmaceutical Industries Reports Q1 Earnings and Announces Acquisition of Amylyx
Teva Pharmaceutical Industries reported first-quarter revenue of $4.0 billion, down 1% year-over-year, with adjusted EBITDA up to $1.1 billion and non-GAAP EPS at $0.53. The company's innovative portfolio grew by 41%, driven by Austedo ($578M), UZEDY (+62%), and AJOVY (+35%). Teva announced a planned acquisition of Amylyx for an upfront payment of $700 million, with potential additional milestones up to $200 million.